Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
Jeffrey A. Allen, MD
University of Minnesota
12:30 MIN
  • CIDP
Understand the challenges associated with accurately diagnosing CIDP
DOWNLOAD PDF
European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
12:15 MIN
  • CIDP
Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
3:00 MIN
  • CIDP
  • MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF
Fatigue in CIDP
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
09:29 MIN
  • CIDP
Engage in a presentation on the comparison between active and remission disease states in CIDP.
DOWNLOAD PDF
NOW PLAYING
12:30
Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
Understand the challenges associated with accurately diagnosing CIDP
Peter
NOW PLAYING
12:15
European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and tr...
Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.
NOW PLAYING
3:00
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

NOW PLAYING
09:29
Fatigue in CIDP
Engage in a presentation on the comparison between active and remission disease states in CIDP.

Our Experts on CIDP

Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Peter Van den Bergh, MD PhD
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
  • CIDP

Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • CIDP
  • GBS
  • MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
Vera Bril, BSc, FRCPC, MD
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
  • CIDP
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
  • CIDP
  • GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

IgG Levels and Wear Off Reflect Administration and Outcome
PDF | 1.5 MB
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
PDF | 2.2 MB
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 421 KB
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
PDF | 250 KB
Back to Top